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Abstract 
Objective: To examine whether an optimised intervention is a more cost-effective option than TAU 
for improving agitation and quality of life in nursing home residents with clinically significant 
agitation and dementia.  
Design: A cost effectiveness analysis within a cluster-randomised factorial study in 69 care homes 
with 549 care home residents was conducted. Each cluster was randomized to receive either the 
WHELD intervention or TAU for nine months. Health and social care costs, agitation and quality of 
life outcomes were evaluated. 
Results: Improvements in agitation and quality of life were evident in residents allocated to the 
WHELD intervention group. The additional cost of the WHELD intervention was offset by the higher 
health and social care costs incurred by TAU group residents (mean difference £2 103; 95% CI -13 to 
4 219).   
Conclusion: The WHELD intervention has clinical and economic benefits when used in residents with 
clinically significant agitation. 
 
Keywords: Alzheimer, Dementia, Costs, Care home, Nursing home, Agitation, Fees.  
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Background 
The vast majority of care home residents have dementia or severe memory problems and the cost of 
supporting them has been estimated to be between £7 and £13 billion annually, depending on the 
proportion of self-funders.1 For all residents, care home fees account for the majority (95%) of the 
costs. Of the services provided by agencies outside the care home, hospital services are the most 
expensive category.  Hospital costs contribute 3% towards the total costs and primary and secondary 
care costs contribute 2%. When care home fees are excluded, almost 50% of the costs are accounted 
for by hospital costs.1 These high costs are not only attributable to having dementia but are also 
associated with comorbidities which can co-occur.  
Neuropsychiatric symptoms are known to occur over the course of dementia.  Behavioural 
symptoms such as agitation, anxiety and aggression, are among some of the most upsetting 
symptoms for individuals with the disease and can have a substantial impact on quality of life.2 
Improving behaviour, functioning and quality of life of residents in care homes pose a challenge for 
care home managers because there are mixed findings from studies evaluating routinely used 
pharmacological and non-pharmacological therapies.  
Anti-dementia medications are widely considered to be effective in people with Alzheimer’s disease 
(AD). Acetylcholinsterase inhibitor (AChEI) (also known as cholinesterase inhibitors) include drugs 
such as donepezil, rivastigmine, memantine and galantamine and combinations of these drugs are 
being used. For people with mild to moderate AD neither galantamine nor rivastigmine had any 
significant effects on behaviour and relative to donepezil or galantamine significantly better effects 
on behaviour was observed with rivastigmine3. When treated with cholinesterase inhibitors modest 
improvements in functioning and clinical global impression were found in people with moderate to 
severe AD4, 5 and in people with severe AD6, 7. Other research into the use of cholinesterase 
inhibitors in people with moderate to severe AD investigated if there were benefits from continuing 
treatment and whether initiating memantine in the course of the disease was beneficial8. Howard 
and colleagues8 found that continued treatment with donepezil was associated with modest 
cognitive and functional benefits, and the start of memantine was associated with significantly 
better impacts on cognition and function, although the magnitude of the advantage was smaller 
than it was with donepezil. 
Although the evidence on cholinesterase inhibitors differs by severity of dementia, the evidence on 
the value of using antipsychotic medications is more conclusive when treating psychiatric symptoms. 
The evidence although riddled with complexity highlights consensus on modest benefits when 
treating psychiatric symptoms and the significant risks of antipsychotic drug use 9-13 . Person centred 
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care has emerged as an alternative way of caring for someone with dementia, and shifts attention 
from behaviour to what may be causing or contributing to the behaviour 14. The Caring for Aged 
Dementia Care Residents (CADRES) study reported a reduction in agitation in nursing home residents 
through personalized care techniques based on an individuals’ preferences and needs. 15 However, 
there have been other studies that have explored the direct impacts of personalized interventions 
on quality of life. 16  
These concerns are important, given scarce resources to determine whether interventions to 
improve the quality of life of care home residents represents good value for money. A systematic 
review of the literature on economic evaluations of dementia found a small number of studies that 
investigate interventions in care home residents, but these tended to focus on a limited number of 
study participants. 17 As part of a review of the literature, one study of care home interventions 
found many manual-based studies but only six were randomized controlled trials (RCTs) 
investigating quality of life as a measure of outcome but none were cost effectiveness studies. 18  
The Well-being and Health for people with Dementia (WHELD) study sought to examine the 
effectiveness and cost-effectiveness of a programme of care combining components intended to 
improve the quality of life of care home residents with dementia and agitation. The components 
included person-centred care, management of agitation and psychosocial approaches. The 
effectiveness findings have been published elsewhere.18 In this article, we examine the cost-
effectiveness of an intervention WHELD with treatment as usual (TAU) to improve the wellbeing of 
people with dementia in care homes. 19  
Methods 
Hypothesis 
The WHELD randomised control trial compared an optimised intervention plus TAU compared to 
TAU for care home residents with dementia and agitation (Cohen Mansfield Agitation Inventory; 20 
CMAI>29).  The current analysis focussed on participants with clinically significant levels of agitation 
(CMAI >40). The economic hypothesis was that the additional cost of WHELD and TAU compared 
with TAU would be offset by the improvements in agitation and quality of life in addition to any 
savings in the use of health and social care services.  
Study design and participants 
WHELD was a two-arm cluster-randomized controlled trial, conducted in 69 care homes, with a 
minimum cluster size of 12 participants. Each cluster was randomized by dynamic allocation to 
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receive either the optimised WHELD intervention or TAU over nine months. There were three 
recruiting hubs based in South London, North London and Buckinghamshire in the UK.  
Participants in the trial met the clinical criteria for dementia as defined by the Clinical Dementia 
Rating 20 with a score greater than 1; were at stage 4 or greater on the Functional Assessment 
Staging; 21 and for the current analysis met the clinical criteria for significant agitation (a score of 
greater than 40, as defined by the CMAI). All residents meeting the eligibility criteria within the 
homes were invited to participate.   
Interventions 
The details of the WHELD intervention are described in detail elsewhere 18. In brief, the WHELD 
intervention was delivered as a streamlined, manualised version of the intervention focusing on 
Person Centred Care (PCC) training for staff; promoting tailored social interaction; and a care home 
based system for triggering appropriate review of antipsychotic medications by General Practitioners 
(GPs). Care home staff received training from a research therapist. Two lead care staff members 
(“WHELD Champions”, also referred to as “Champions”) were nominated in each care home and 
received support from the therapist over a period of four months (one training day per month). The 
staff also received so additional coaching, supervision and regular review with the therapist over the 
nine-month period. The Champions were then responsible for the delivery and dissemination of the 
intervention in each care home. In addition, GPs associated with each home were sent educational 
materials about the programme but there were no proactive education sessions delivered by the 
research team.  
The delivery of the WHELD intervention was adapted for the care setting and involved: stand-alone 
training sessions, modelling skills, building sessions into daily routines, working with the resident to 
develop activities that are personalized and tailored to meet their needs, care home team 
formulation, medication review and goal planning sessions.  
The care homes in the control group received treatment as usual (TAU) alone. Treatment as usual 
was provided by service providers external to the care home and included a range of health and 
social care services such as hospital inpatient, outpatient, day hospital, accident and emergency 
services, primary care, community health care and social care services.  
Outcomes 
The primary measure of outcomes at baseline (before randomisation) and at nine months following 
randomisation was quality of life measured by the DEMQOL proxy, 22,23 which assesses the health-
related quality of life (HRQoL) of people with dementia. A secondary measure of outcome was 
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agitation, measured by the Cohen-Mansfield Agitation Inventory (CMAI), which is a caregiver’s rating 
questionnaire to specify agitated behaviour.  
Resource use and costs 
Economic data for each individual in the study was collected using an adapted version of the Client 
Service Receipt Inventory (CSRI) which has been used in previous studies of care home residents 
with dementia. 1, 24, 25 It includes questions about the resident’s sociodemographic profile, care home 
charges, and use of health and social care services. It was administered retrospectively at two data 
collection time points: by interview at baseline covering the previous three-month period and nine 
months after randomization (covering the previous three months). In addition, the staffing inputs of 
the WHELD intervention were measured and included time spent by the therapist and champion in 
training, supervision and preparation.  
Total costs for each care home resident were derived by summing three main cost categories: 
intervention costs, resident fees and costs of health and social care services provided by 
organisations external to the care homes.  
The intervention cost for each home was apportioned across the number of study participants in the 
care home to derive an intervention cost for each care home resident in the study. To these costs we 
added the cost for an antipsychotic review for those allocated to the WHELD intervention and TAU 
and were on antipsychotics during the trial. The Champions were likely to be staff from different 
professions within the care home. For each of these professions we obtained separate data on the 
professional’s cost per hour and derived an average cost per hour for a Champion and that of a 
therapist. Data on the time inputs for training, supervision and delivery of the WHELD intervention 
was combined with the cost per hour for each professional who conducted the following: received 
the training, were supervised and were involved in the supervision, and those who delivered the 
intervention. The supervisors were also supervised by three senior principal investigators during the 
study. These research-related costs were not included. 
The resident fees were collected from the care homes. Where data on study resident’s fees could 
not be elicited, we asked the care home for the typical weekly fee for residents with a similar level of 
need to the participant in the study. Where both of these data were missing, the resident’s fees 
were imputed based on the average fee for study residents in that care home. Weekly fees were 
extrapolated to a nine-monthly figure.  
Total health and social care costs consisted of services provided by agencies external to the care 
home: hospital inpatient, outpatient, day hospital, accident and emergency services, primary care, 
community health care and ambulatory care. Services and support costs provided by external 
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agencies were calculated by multiplying the frequency and intensity of resources collected from the 
CSRI by appropriate unit costs. Unit costs (2014/2015 price level) were obtained from widely used 
published sources (Table 1) 26, 27. 
Cost-effectiveness analysis  
The primary economic evaluation at nine months (i.e. a cost-effectiveness analysis) included cost 
and outcomes for the two randomisation groups - the WHELD intervention and TAU - from a health 
and social care perspective. The cost effectiveness analysis focused on two outcomes: CMAI and 
DEMQOL proxy. Societal weights were applied to DEMQOL proxy scores 28 to calculate utility values. 
Quality-adjusted life years (QALYs) were calculated by ‘area-under-the-curve’ analysis, with linear 
interpolation between baseline and nine-months follow up assessments points.  
Statistical analyses  
Analyses were conducted on residents allocated to the care homes receiving the WHELD 
intervention and TAU. Residents were analysed in groups to which they were allocated irrespective 
of drop out.  
We imputed CMAI scores at follow up for participants with clinically significant agitation who did not 
have follow up CMAI data, in the following way.  Figure 1 The CONSORT diagram (Figure 1) shows 
the people with and without clinically significant agitation who were assessed at follow-up and on 
whom a complete case clinical analysis was conducted. Of those 257 (WHELD + TAU) and 296 (TAU); 
200 (WHELD + TAU) and 181 (TAU) participants had clinically significant agitation. We imputed CMAI 
scores for those who did not have follow up CMAI data and needed to have their scores imputed: 67 
(25.1%) (WHELD + TAU) and 101 (35.8%) (TAU).  
The missing service use data (either contacts or duration of contact) and outcomes were imputed to 
facilitate the estimation of subtotal and total costs. Ordinary Least Squares (OLS) regression-based 
single imputation - with a variety of baseline covariates including personal characteristics, value of 
variable being imputed and care home indicator - was used to impute missing values at follow-up 
assessment  
For the base case model we selected individuals in the study with a CMAI score >40 and ran 
multilevel mixed effect models. In the cost and outcome models, we controlled for baseline values of 
cost, outcomes, site and age. The adjusted total health and social care cost and outcomes models 
also included the treatment variable as a random effect at the care home level. We accounted for 
clustering by allowing the model intercept and treatment variable coefficient (i.e. treatment effect) 
to vary by care home. 
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The cost-effectiveness of the WHELD intervention and TAU compared to TAU alone was evaluated 
by calculating incremental cost-effectiveness ratios (ICERs). The ICER is defined as the between 
group difference in mean costs divided by the between group difference in mean outcome. 
Incremental cost-effectiveness ratios were calculated in turn for each measure of outcome: QALY 
and CMAI. Using these ratios, we were able to determine a cost per unit improvement in QALY and 
the cost per point improvement in agitation (CMAI scale).  
Bootstrapping was conducted with the mixed effects models to generate confidence intervals that 
can be used to capture parameter uncertainty around the estimates in the cost-effectiveness 
analysis. The 1000 treatment effect replications from this bootstrapping process were plotted on 
cost-effectiveness planes and used to construct cost-effectiveness acceptability curves (CEAC), which 
are also standard practice in trial based economic evaluations.29  
Cost-effectiveness acceptability curves  
The CEAC is an established construct for presenting parameter uncertainty. The willingness-to-pay 
threshold ICERs are shown on the horizontal axis and give hypothetical values of societal willingness-
to-pay for each additional unit increase in outcome per average patient. 30,31 The vertical axis gives 
the probability that the WHELD intervention and TAU is relatively  cost-effectiveness relative to TAU 
alone at each of these threshold ICERs. Using the net benefit approach, monetary values of 
incremental effects and incremental costs were combined, and net benefit (NB) derived as: NB = λ x 
(effectb - effecta) – (costb – costa); λ is willingness-to-pay for a unit improvement in effectiveness 
(CMAI, QALYs), and ‘a’ and ‘b’ denote TAU and WHELD interventions, respectively.  
The data analyses were conducted using SPSS for Windows release 12.0.1 (SPSS Inc., Chicago, IL, 
USA; 1989-2001) and STATA 14 for Windows (StataCorp, College Station, TX, USA; 1985 – 2004).  
Sensitivity analyses  
To explore the sensitivity of the results to alternate statistical methods the analyses were repeated 
using an OLS model with cluster adjusted standard errors. This included the same control variables 
as those in the base-case model.  
Results 
Participants  
971 residents had their care homes randomised as shown in the Consolidated Statement of 
Reporting Trials (CONSORT) (Figure 1). Of the 971 residents, 549 residents (57% of residents 
recruited to the trial) met the clinical criteria for agitation at baseline. Of those residents with a 
clinically significant agitation, there were 282 residents in the TAU group and 267 in the WHELD 
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intervention and TAU group. The baseline characteristics were broadly comparable across the 
intervention arms (Table 2). 
For those with clinically significant agitation, there was a high response rate for service use data 
collected at both assessment time points. At baseline, in the TAU group service use data was 
collected on 281 (99.6%) care home residents. For one (0.4%) individual in this group no service use 
data was collected and in the intervention group service use data was collected on 267 (100%) 
residents. At nine months, the number of care home residents with any service use data in the TAU 
group fell to 231 (82%) and in the intervention group there were 199 (75%) individuals.  
Costs and cost effectiveness 
The additional cost of delivering the intervention compared to TAU was £2, 629 (SD 516). The 
majority (53% or £1, 367) of these costs related to the time the Champion spent in training and 
receiving feedback from the supervising therapists. The therapist time spent preparing for the 
training, actual training and supervision of the Champion contributed the remaining 47% (£1, 262) of 
the cost.  
There were notable changes in the pattern of health and social care cost over the time of the study. 
The health and social care costs for residents in the TAU group were 1.2 times higher (£34 215) than 
those in the WHELD intervention and TAU group (£29 483) in the nine-month period following 
intervention. However, the unadjusted difference in total health and social care costs including the 
intervention did not achieve statistical significance (£2 103; CI -13 to 4 219). The WHELD intervention 
conferred a significant improvement in agitation and quality of life compared to treatment as usual. 
The unadjusted difference in CMAI score was 5.16 (95% CI 1.11 to 9.20, p=0.01) and for DEMQoL-
proxy score, 3.23 (95% CI -5.54 to -0.93, p=0.01) (Table 3).  
In the base case analysis we compared the intervention using multilevel mixed models adjusting for 
a range of covariates and found that the additional costs incurred by the WHELD intervention did not 
result in significantly higher overall costs to health and social care relative to TAU alone, but 
provided QALY gains and improvements in agitation (Table 4). As compared with TAU, the WHELD 
intervention was no more costly (95% confidence interval [CI], -2 578 to 179) per person and 
provided an additional 0.01 QALYs per person (95% CI, 0.001 to 0.018) and 3.72 points of 
improvement in agitation per person (95% CI, 1.15 to 6.38); the corresponding ICERs were -£137 978 
per QALY gained (95% CI, -733 656 to 34 483) and -£348 per point improvement in agitation (95% CI, 
-1 156 to 79). 
The CEACs showed that the probabilities of cost-effectiveness across a wide range of a decision 
maker’s willingness to pay for a unit improvement in outcome. These were similar for both outcome 
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measures. Comparing costs and both measures of outcome in turn, the WHELD intervention and 
TAU was consistently the dominant intervention (Figures 2-3). The CEAC for QALYs  started at 95% 
probability that WHELD and TAU is relatively cost-effective compared to TAU alone and this 
gradually rose to 100% at a willingness-to-pay threshold ICER of £70 000 for each QALY gained 
(Figure 4). If decision makers were willing to pay £200 for each point improvement in agitation the 
probability that the WHELD intervention and TAU is cost effective is as high as 100% (Figure 5).  
Sensitivity analysis  
The OLS models with cluster robust standard errors produced broadly similar results to the 
multilevel models for clinical outcomes. QALY and CMAI models gave similar results to the base case 
(QALY: coefficient 0.009; p = 0.01; 95% CI -0.000 to 0.021; CMAI: coefficient -3.49; p = 0.04; 95% CI 
0.33 to 6.985). The WHELD intervention and TAU was no more costly than TAU (p = 0.51; 95% CI -2 
680 to 1 094).  
Discussion 
This is the first cost effectiveness study to report on the value to nursing home residents of using 
interventions which consider the reduction of antipsychotic use.  A recently published systematic 
review highlighted the lack of clinical and economic reporting of antipsychotic use in nursing 
homes.32 
In the WHELD factorised controlled trial of 549 care home residents with dementia and clinically 
significant agitation (CMAI>40), we found that the WHELD intervention when added to treatment as 
usual was more cost effective than treatment as usual alone, when considering health and social 
care costs and improvements in QALYs and agitation.  
Costs and cost effectiveness 
The evaluation of costs found that the additional intervention costs resulted in notable changes in 
the pattern of health care over the time of the study. There were higher health and social care costs 
in the TAU group compared to those in the WHELD intervention group suggesting that the additional 
costs of the intervention resulted in health and social care cost savings when direct action is taken to 
improve the quality of life and agitation of residents with dementia living in care homes. Both 
agitation and QALYs improved significantly over the intervention period.  The assessment of cost 
effectiveness and parameter uncertainty confirmed that the WHELD intervention and TAU would 
have a higher probability of being cost effective compared to TAU alone for a wide range of societal 
willingness-to-pay thresholds. The results were broadly similar when using multilevel modelling and 
OLS models. The largest difference between the methods was shown in the results for costs: the 
11 
 
difference in costs was around £400 less in the OLS model with the bootstrapped confidence interval 
crossing 0 to the positive part of the number line. There was more uncertainty when using the OLS 
model approach around the conclusion that the WHELD intervention was cheaper. When the impact 
of the WHELD intervention on agitation and quality of life were considered, the WHELD intervention 
was more effective than TAU.  These results are mainly relevant to residents with clinically 
significant agitation in dementia and may be less so for residents for whom agitation is less severe.  
Strengths and limitations 
We adopted a health and social care perspective which can be used to inform reimbursement 
decisions, particularly in sectors with overstretched budgets. A health and social care viewpoint is 
also in line with the approach adopted by decision makers in Europe, Australia and Canada.33 Despite 
the widespread use of such a narrow point of view which considers only the cost and outcome 
impacts to health and social care, there is some recognition that decisions that are made using 
evidence that omit the impacts to other stakeholders such as caregivers for example, could 
potentially result in welfare losses to these stakeholders.  
Consistent with a health and social care viewpoint, we did not include any costs to unpaid carers of 
the care home residents. We know from published research that the time spent by relatives and 
friends providing unpaid support to care home residents is not insubstantial; with one estimate 
suggesting that unpaid caregivers spend an average of 36 hours per month providing support to 
individuals in long term care settings 34. However, we also recognise that there are theoretical 
challenges - noted in detail elsewhere 35,36 -to including the costs and effects that fall more widely on 
society.  
In the economic evaluation the DEMQoL-proxy was used as the measure of outcome on which to 
derive QALYs. We were unable to use the study participant’s report of their own quality of life 
assessed using the DEMQoL to derive QALYs, as there was a high degree of missing data (83% 
missing entries), whereas the proxy data had only a third of entries missing. The cost effectiveness 
finding was therefore dependent on who was reporting quality of life as there are important 
differences between self-report and carer-proxy reports which suggest that these questionnaires 
cannot necessarily be used interchangeably.37 Therefore, these results should be interpreted with 
caution.  
It is important to note that this economic evaluation covers a nine-month follow-up period and 
although this is a relatively long time in the context of trial-based evaluations; additional research 
would be required to investigate even longer term trends and increments. The authors are not 
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aware of any model-based evaluations of optimised interventions such as WHELD in nursing home 
residents with dementia.        
Conclusions 
The WHELD intervention trial offers new evidence on costs and outcomes in the use of an optimised 
intervention which focused on changing the culture in care homes through the use of a Champion. 
The trial suggests a strong case for the introduction of the WHELD intervention – not only on clinical 
grounds but also on economic grounds – for residents with clinically significant agitation.  This is of 
relevance for commissioning bodies given the findings on cost effectiveness. For example, a report 
jointly produced by the British Geriatrics Society and the Care Quality Commission, revealed a patchy 
and chaotic approach to commissioning and providing health care services for care home residents. 
There were missing services and care gaps identified by the report which included medication review 
and care planning. This study has shown that proactive medical review and more responsive support 
for care home residents can reduce inpatient admissions and emergency hospital admissions, while 
improving the outcomes of residents. However, further research is needed to build a better 
understanding of how these interventions impact the quality of life of the care home resident living 
with severe agitation and dementia.  
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Table 1. Unit costs (2014/2015 prices) 
Service Unit cost 
2014/2015 
Hospital visit; per night 23 608 
Accident and emergency; per visit23 44 
Day hospital; per attendance 22 704 
Outpatient attendance; per attendance 22 112 
Memory clinic; per hour 22 424 
Paramedic; cost per attendance22 99 
District nurse; per minute 22 0.73 
Practice nurse; per minute 22 0.72 
Specialist nurse; per minute 22 0.87 
Physiotherapist; per minute 22 0.57 
GP; per minute 22 3.20 
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Table 2. Baseline resident characteristics by intervention arm  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WHELD intervention  
and TAU 
TAU alone 
Age in years, mean (sd) 
n=267 
85 (8.9) 
n=282 
84 (9.0) 
Gender (male); n (%) 
n=267 
91 (34) 
n=282 
82 (29) 
Ethnicity (white) n (%) 
n = 267 
253 (95) 
n=282 
271 (96) 
Marital status (married/long-term partnership) 
n (%) 
n=263 
59 (22) 
n=279 
67 (24) 
Next of kin: yes; n (%) 
n= 267 
254(95) 
n=282 
267 (95) 
CMAI score, mean (sd) 
n= 267 
59 (18) 
n= 282 
61 (19) 
CSDD score, mean (sd) 
n= 264 
8 (5) 
n= 279 
8 (5) 
CDR score, mean (sd) 
n= 267 
14 (3) 
n= 282 
14 (4) 
NPI – score, mean (sd) n= 264 
21 (16) 
n= 279 
21 (16) 
DEMQoL proxy, mean (sd) 
n= 264 
99 (13) 
n=281 
98 (12) 
DEMQoL score, mean (sd) 
n=84 
85 (18) 
n=79 
86 (16) 
Total health and social care costs, £; mean (sd)  
n= 266 
9, 979 (2 579) 
n= 282 
11, 013 (4 627) 
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Table 3 Unadjusted mean costs and mean cost differences at baseline and over 9 months (£, 2014 – 2015) 
 WHELD intervention  
and TAU 
TAU alone WHELD Intervention and TAU  
vs TAU alone 
Cost categories Mean (£) SD  
(£) 
Mean (£) SD 
 (£) 
Unadjusted 
mean difference 
(£) 
95% CI 
Baseline – 3 months (n=549)     
Total health and social care costs 9 980 (2 579) 11 013 (4 627) -1 033 ( 409to 1 658) ^ 
WHELD intervention  2 629 516 
- - 
2 629 
(-2 701 to -2 557) 
^ 
Follow up - 9-months (n=430)     
  Accommodation fee 28 382 (10 851) 32 723 (11 142) -4 341 ( 2 252 to 4 630) ^ 
  Hospital  273 (1 238) 325 (1 582) -52 (-216 to 320) 
  Primary care  701 (300) 1 007 (270) -306 (-251 to 360) 
  Community health  81 (297) 72 (229) 9 (-60 to 42) 
  Emergency  46 (110) 88 (222) -42 ( 10 to -75) 
Total health and social care costs incl. 
intervention costs 
32 112 (10 961) 34 215 (11 326) -2 103 (-13 to 4 219) 
^significant at p<0.05 
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Table 4 Mean adjusted incremental cost and effect, and cost-effectiveness ratios (£, 2014/2015) 
over 9 months 
 
WHELD Intervention and TAU vs  
TAU alone 
Mean incremental cost* (£, 2014/15 prices) mean (95% CI) 
     Health and social care -1 294 (-2 577 to 179) 
Mean Incremental effect (95% CI)* 
CMAI score (reversed so higher scores mean better 
outcomes) 
3.72 (-1.15 to 6.38) 
DEMQoL – Proxy score (higher scores better outcomes) 
1.96 (0.38 to 3.24) 
Incremental cost-effectiveness (£, 2014/2015 prices)*  
   Health and social care cost/CMAI -348 (-1709 to -107) 
   Health and social care cost/ QALY  -137 978 (-733 656 to 34 483) 
*Adjusted for site, age, gender, CMAI score before and randomisation and total costs at baseline. 
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Figure 1. CONSORT diagram showing flow of participants through the study. TAU arm – treatment 
as Usual. WHELD arm – WHELD plus TAU. Abbreviations: WHELD, Well-being and Health for 
People with Dementia; TAU, treatment as usual 
 
  
 18 
 
Figure 2. Scatter plot: WHELD intervention and TAU vs. TAU alone; health and social care 
perspective, with effectiveness measured in QALYs 
 
Figure 3. Scatter plot: WHELD intervention and TAU vs. TAU alone; health and social care 
perspective, with effectiveness measured in CMAI 
 
 
Figure 4. Cost-effectiveness acceptability curve: WHELD intervention and TAU vs. TAU alone; 
health and social care perspective, with effectiveness measured in QALYs 
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Figure 5. Cost-effectiveness acceptability curve: WHELD intervention and TAU vs. TAU alone; 
health and social care perspective, with effectiveness measured in CMAI 
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